New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Rusfertide’s big readout will now not come until 2025.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.